Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of NS11821 in healthy men
NL-OMON33125Phase 1Active, not recruiting
- Sponsor
- NeuroSearch
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NS11821 in anxiety disorder, sponsored by NeuroSearch. Primary endpoints: Adverse events, Vital signs and 4 more. Started Aug 2009; status: active, not recruiting.
02
Drugs
NS11821
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on NL-OMON33125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33125.